SCHEMBL4020754

SCHEMBL4020754

O=C(O)CN(Cc1cccc(C(F)(F)F)c1)Cc1ccc(S(=O)(=O)NCCc2ccc(Oc3ccccc3)cc2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.42
MCL1 Q07820 1/20 0.41
LTA4H P09960 1/20 0.41
EPHX2 P34913 1/20 0.41
FFAR1 O14842 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
PPARG P37231 3/20 0.40
PPARA Q07869 3/20 0.40
AKR1C3 P42330 1/20 0.40
NR3C1 P04150 2/20 0.38
PGR P06401 1/20 0.38
AR P10275 1/20 0.38
ESR2 Q92731 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
CA12 O43570 1/20 0.38
CA4 P22748 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1855180 0.88 MAPK14 (0.43) MAPK14MCL1LTA4HEPHX2FFAR1
SCHEMBL4713555 0.80 MAPK14 (0.41) MAPK14MCL1LTA4HEPHX2FFAR1
SCHEMBL1852016 0.79 SERPINE1 (0.42) PPARGNR3C1KDM4EERBB2ERBB4
SCHEMBL5048907 0.76 GUSB (0.44) LTA4HEPHX2AKR1C3NR3C1PGR
SCHEMBL1854510 0.76 LPAR1 (0.45) LTA4HEPHX2AKR1C3NR3C1PGR
SCHEMBL1852522 0.73 TRPM8 (0.43) PPARGNR3C1MEN1KMT2A
SCHEMBL4024326 0.73 MAPK1 (0.46) FFAR1FFAR4PPARGNR3C1TBXAS1
SCHEMBL5040032 0.73 ERBB2 (0.42) FFAR1FFAR4MEN1KMT2AKDM4E
SCHEMBL4019783 0.70 MAPK1 (0.41) FFAR1FFAR4NR3C1KMT2AKDM4E
SCHEMBL6719223 0.70 SMN1; SMN2 (0.49) EPHX2CA9CA12MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US claimed
EP-1732534-B1 USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS SERONO LAB (CH) 2008-07-23 EP claimed
US-20070185118-A1 Use of methylene amide derivatives in cardiovascular disorders APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 MAPK14 1786/4885MCL1 1601/4885LTA4H 536/4885
US-20070185118-A1 Use of methylene amide derivatives in cardiovascular disorders TNNI3, TNNT2, ADM2 MAPK14 2807/4885MCL1 2750/4885LTA4H 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.